Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of TMDX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter May 19, 2020
Questions asked 25 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 25 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 0 of 2 closing letter

Form S-3

2020-05-19 to 2020-05-19 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
Registration Statement on Form S-3, filed on May 6, 2020 · General
SEC asked
We note that pursuant to General Instruction I.A.3 you were not eligible to use Form S-3 on the date you filed your registration statement as you will not have been a reporting company for twelve months until June 1, 2020. Please amend your registration statement onto a Form for which you are eligible, or please withdraw your registration statement and refile it as of a date that you are eligible to use Form S-3.
Rest of the question

For further guidance, please refer to Securities Act Rule 401 and Securities Act Forms CDI 115.06.

TMDX answered
We acknowledge the Staff’s comment and respectfully submit that the Company has been subject to the reporting requirements of the Exchange

Act of 1934, as amended (the “Exchange Act”), for at least a full twelve months. The Company’s registration statement on Form S-1 (File

No. 333-230736) related to its initial public offering of common stock (the “S-1 Registration Statement”), and its registration statement on Form 8-A (File No.
Rest of the answer

000-38891) (the “Form 8-A Remigration Statement,” and together with the S-1 Registration Statement, the “IPO Registration Statements”), each became effective on May 1, 2019, and therefore the Company has been subject to the reporting requirements of Sections 12 and

15(d) of the Exchange Act for at least twelve full calendar months. Prior to the filing of the Registration Statement, Ropes & Gray LLP, counsel to the Company, consulted with the Office of the Chief Counsel in the Division of Corporation

Finance who concurred with the Company’s position that because the IPO Registration Statements became effective on May 1, 2019, the Company was subject to the Exchange Act reporting requirements for the full month of May 2019. Accordingly, the Company was eligible to file a Form S-3 as early as May 1, 2020.

Read in the reply

Also in this review: company letter, May 19, 2020

Form S-1

2018-11-15 to 2019-04-29 · 24 questions · 2 letters from the SEC, 4 from the company
No closing letter
RevenueResults discussion (MD&A)DebtInventorySegmentsLegal and contingenciesDerivatives and hedging
Draft Form S-1 submitted on October 19, 2018 · Industry and Market Data, page ii
SEC asked (1)
Please tell us whether you commissioned any of the third-party data included in your registration statement.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Our Business, page 1
SEC asked (2)
We note your disclosure that you have developed a "substantial" body of clinical evidence supporting effectiveness and safety of your OCS product. Since efficacy and safety are determinations within the authority of the FDA, it is not appropriate to make these claims to the extent you have not received approval for certain indications discussed.
Rest of the question

You may describe the primary and secondary endpoints of any clinical trials, provide data indicating the achievement of the endpoints and any statistical measures relating to the significance of the data.

TMDX answered

No numbered answer found in the reply. Read the reply ↗

Our Business, page 1
SEC asked (3)
Please provide a more detailed discussion of underlying assumptions used in your addressable market calculation.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Risks Associated with Our Business, page 7
SEC asked (4)
Please revise the first bullet point in this section to quantify your operating losses for the most recent period and your total accumulated deficit.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Implications of Being an Emerging Growth Company and Smaller Reporting Company, page 8
SEC asked (5)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Our existing and any future indebtedness..., page 15
SEC asked (6)
Please describe the applicable covenants from your credit agreement with more specificity and include a discussion of the potential risks relating to the financial covenant mentioned on page 80.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 55
SEC asked (7)
Please provide more specific disclosure regarding the intended advancements in clinical trials and the continued development and commercialization of your OCS products. As examples only, provide more detail regarding the clinical trials you plan to pursue, whether new or existing, whether you believe the proceeds will be sufficient to complete the clinical trials, and how you intend to continue developing your
Rest of the question

products. Dilution, page 60

TMDX answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 55
SEC asked (8)
Please expand to disclose how the amounts and percentages in the second table would change assuming the exercise of all outstanding options and warrants. Net Revenue, page 72
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 55
SEC asked (9)
Revise here and on page 75 to provide the relative growth rate in revenue of consoles versus disposable sets for each of the three OCS product classes. Also, quantify the extent to which change in price for each OCS product class affected your revenue.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Stock-Based Compensation, page 84
SEC asked (10)
We note your disclosure on page 86 related to the stock options granted between January 1, 2017 and September 29, 2018. When pricing information for this offering is available, please tell us the significant reasons for any material differences between your last fair value determination and the mid-point of the estimated IPO price range. Clinical Evidence, page 105
TMDX answered
The Company respectfully submits the below additional information to assist the Staff in its review of the Company’s position with respect to its determination of the fair value of the common stock underlying outstanding equity awards of TransMedics, Inc.

(“TransMedics”), the Company’s current direct parent and, upon the corporate reorganization described in the Registration Statement (the “Corporate Reorganization”) to occur immediately prior to or concurrently with the closing of the Company’s initial public offering (the “IPO”), the direct, wholly-owned subsidiary of the Company, and the
Rest of the answer

reasons for the differences between the most recent fair value determination of

TransMedics’ common stock and the estimated offering price for the Company’s IPO.

Preliminary IPO Price Range

The Company supplementally advises the Staff that, based on discussions with the board of directors (the “Board”) of the Company and in part on input provided by the underwriters, the Company currently anticipates that the price range for the IPO is expected to be within the range of $[***] to $[***] per share (the “Preliminary Price Range”), before giving effect to the conversion of all of the capital stock of TransMedics into shares of common stock of the Company at a conversion rate, which is expected to be [***]-for-one with respect to common stock, pursuant to the Corporate Reorganization. The actual price range to be included in a subsequent amendment to the Registration Statement (which will comply with the Staff’s interpretation regarding the parameters of a bona fide price range) has not yet been determined and remains subject to adjustment based on factors outside of the Company’s control. However, the Company believes that the foregoing indicative price range will not be subject to significant change.

TMDX-002

Determining the Fair Value of Common Stock Prior to the IPO

As there has been no public market for the Company’s or TransMedics’ common stock to date, the estimated fair value of TransMedics’ common stock has been determined by the Board of TransMedics as of the date of each option grant, with input from management, considering TransMedics’ most recent third-party valuations of its common stock and the Board’s assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant.

As disclosed in the Registration Statement, TransMedics’ most recent third-party valuation of its common stock was prepared as of October 9, 2018

(the “October 9, 2018 valuation”). This third-party valuation was performed in accordance with the guidance outlined in the AICPA’s Accounting and Valuation Guide, Valuation of Privately-Held-Company

Equity Securities Issued as Compensation, and was prepared using a Monte Carlo simulation method. The Board of TransMedics relied, in part, on the results of the October 9, 2018 valuation in its determination of the fair value of common stock of $2.47 per share as of October 9, 2018, when it granted options for the purchase of an aggregate of 319,000 shares of common stock.

The

October 9, 2018 valuation considered two future-event scenarios: an IPO scenario and a merger and acquisition (“M&A”) scenario. The enterprise values of the Company in the IPO scenario and the M&A scenario were determined using a market approach and an income approach, respectively. The IPO scenario assumed that all shares of preferred stock would convert into shares of common stock and would no longer have the liquidation preferences and preferential rights attributable to the shares of preferred stock as compared to the shares of common stock prior to the IPO. The October 9, 2018 valuation probability weighted the IPO scenario at [***]% and the M&A scenario at [***]%. The [***]% weighting of the IPO scenario was selected due to the high perceived risk, at that time, of successfully completing an IPO in the near term, given significant uncertainties that needed to be resolved before commencing an IPO, which are discussed below.

For the two future-event scenarios, TransMedics then applied a discount for lack of marketability of [***]%, in each case determined by a put option analysis that considered the timing of each future-event scenario. The October 9, 2018 valuation resulted in a valuation of TransMedics’ common stock of $2.47 per share.

Comparison of Most Recent Valuation and the Preliminary Price Range

As is typical in initial public offerings, the Preliminary Price Range was not derived using a formal determination of fair value, but was determined based in part upon discussions between the Company and the underwriters. Prior to April 5, 2019, the Company and the underwriters had not had any specific discussions regarding the Preliminary Price Range. The factors considered in setting the

Preliminary Price Range included:

● a fundamental analysis of the Company’s business, financial condition and prospects;

estimates of business potential and earnings prospects for the Company and the industry in which it operates;

TMDX-003 an analysis of the typical valuation ranges and performance of recent initial public offerings for companies in the medical device industry;

the general condition of the securities markets and the recent market prices of, and the demand for, publicly traded common stock of generally comparable companies;

the Company’s belief that the public trading market would remain receptive to companies in the medical device industry; and the Company’s belief that there would be sufficient demand for the Company’s common stock to support an offering of the size contemplated by the Company.

The Company believes that the difference between the fair value of the common stock of TransMedics of $2.47 per share as of October 9, 2018 and the Preliminary Price Range of $[***] to $[***] per share is the result of the factors listed above and the following factors and positive developments with respect to the

Company’s business that occurred subsequent to October 9, 2018:

The Preliminary Price Range is based only upon a scenario in which the Company completes the IPO and is not probability weighted, in contrast to the October 9, 2018 valuation that considered multiple potential outcomes, which would result in a lower valuation of TransMedics’ common stock compared to the IPO price. In the October 9, 2018 valuation, the probability weighting of the IPO scenario was [***]% for the reasons described above. If TransMedics had instead applied a weighting of 100% to the IPO scenario, the fair value of the TransMedics’ common stock in the

October 9, 2018 valuation would have been $[***] per share (before giving effect to any discount for lack of marketability).

The Preliminary Price Range necessarily assumes that the IPO has occurred and that a public market for the

Company’s common stock has been created, and, therefore, excludes any discount for lack of marketability of the Company’s common stock or impact of the time value of money, which were appropriately taken into account in the October 9,

2018 valuation.

The Preliminary Price Range assumes the conversion of all outstanding shares of preferred stock of TransMedics into common stock of the Company upon the consummation of the Corporate Reorganization to occur immediately prior to or concurrently with the closing of the Company’s IPO. Such conversion will eliminate the superior rights and preferences of

TransMedics’ preferred stock as compared to its, and the Company’s, common stock.

On October 16, 2018, TransMedics generated its first commercial sale of Organ Care System

(“OCS”) Lung products in the United States and since that date has increased commercial sales of OCS Lung products in the U.S. for the use of the OCS Lung for donor lungs currently utilized for transplantation.

Since October 9, 2018, TransMedics has had important interactions with the U.S. Food and Drug Administration

(the “FDA”) regarding its supplement for the OCS Lung

TMDX-004 premarket approval (“PMA”) application for new indications on the OCS Lung and its first PMA application for the OCS Heart. These interactions with the FDA, which are further described below, have clarified the information that the FDA will require in order to complete its review of these PMA applications in order to determine whether there is reasonable assurance that the OCS is safe and effective for its intended uses. Through these interactions, TransMedics has advanced the regulatory process for the OCS Lung for an important new indication and has initiated the regulatory approval process for the OCS Heart for initial commercial use in the U.S.

Based on the following, TransMedics expects FDA action over the next 18 months on these PMA applications.

In November 2018, TransMedics received from the FDA a major deficiency letter regarding its PMA supplement to its

PMA application for the use of the OCS Lung for donor lungs currently unutilized for transplantation. Importantly, in this major deficiency letter, and the subsequent Day-100 meeting between TransMedics and the FDA in November 2018, the FDA did not require TransMedics to complete additional clinical trials prior to the FDA making its determination of the safety and effectiveness of the OCS Lung for donor lungs currently unutilized for transplantation.

In March 2019, TransMedics responded to this major deficiency letter. TransMedics believes its response addressed each of the questions raised by the FDA in order to continue to advance the regulatory approval process for the OCS Lung.

In December 2018, TransMedics submitted a PMA application to the FDA for the use of the OCS Heart for donor hearts currently utilized for transplantation and donor hearts donated after brain death that are currently unutilized for transplantation. In March 2019, TransMedics received a major deficiency letter from the FDA regarding this PMA application, and the Company intends to respond to the FDA in the second half of 2019 in order to continue to advance the regulatory approval process for the OCS Heart.

Since October 9, 2018, TransMedics has also received approval of investigational device exemptions

(“IDE”) for certain additional studies related to the OCS Heart for use of certain donor hearts that are currently unutilized for transplantation, including donor hearts that are donated after circulatory death. As a result of these

IDE approvals, the Company obtained an additional revenue source because transplant centers purchase OCS disposable sets for use in these clinical studies.

In late October 2018, TransMedics submitted a supplement to the IDE application for the OCS Heart EXPAND Trial proposing to conduct a new continued access study, referred to as the Continued Access Protocol to the OCS Heart Trial for the preservation of certain donor hearts that are currently unutilized for transplantation. In January 2019, the FDA notified TransMedics that the IDE supplement was approved with conditions. In February 2019, the FDA notified TransMedics that the FDA had reviewed TransMedics’ amendment to the IDE supplement and that the IDE supplement was approved with no conditions.

In November 2018, TransMedics submitted an IDE application for a study of the OCS Heart for donor hearts that are donated after circulatory death. In

TMDX-005

December 2018, the FDA notified TransMedics that the IDE application was approved with conditions. In February 2019, the FDA notified TransMedics that the FDA had reviewed

TransMedics’ amendment to the IDE application and that the IDE application was approved with no conditions.

Between mid-November 2018 and mid-January 2019, TransMedics held many “testing the waters” meetings, from which the Company received feedback from potential investors, including feedback regarding the Company’s clinical data, regulatory pathway and revenue growth, which resolved some of the Company’s uncertainties about successfully completing an IPO in the near term.

The proceeds of a successful IPO would substantially strengthen the Company’s balance sheet by increasing its cash resources. In addition, the completion of the IPO would provide the Company with ready access to the public equity and debt markets.

In conclusion, the Company respectfully submits that the deemed per share fair value used as the basis for determining stock-based compensation expense in connection with TransMedics’ grants of equity awards is reasonable and appropriate for the reasons described herein and in the Registration Statement. Further, in light of the proposed IPO, if it were determined that the actual fair value was equal to the high end of the Preliminary Price Range rather than the fair value that was utilized, the Company believes that any resulting increase in stock-based compensation expense would not be material to its consolidated financial statements, as options to purchase only 319,000 shares of TransMedics common stock with an exercise price of $2.47 per share, the fair value of the TransMedics common stock on October 9, 2018, were granted from October 9, 2018 through the date of this letter.

Because of the financially sensitive nature of the Preliminary Price Range and certain other information herein, the Company requests confidential treatment under 17 C.F.R. § 200.83 of the contents of this letter and has submitted a separate request for confidential treatment in accordance therewith to the Commission’s Office of Freedom and Information Privacy Act

Operations. Pursuant to Rule 418 under the Securities Act of 1933, as amended (the “Securities Act”), the information contained in this letter is being provided to the Commission on a confidential supplemental basis only and is not to be filed with or deemed part of the Registration Statement. The Company respectfully requests that the Staff return the unredacted version of this letter to the Company pursuant to Rule 418 of the Securities Act once the Staff has completed its review. We have provided a self-addressed stamped envelope for this purpose. Kindly acknowledge receipt of this letter by stamping the enclosed copy of this letter and returning it in the envelope provided.

Read in the reply
Stock-Based Compensation, page 84
SEC asked (11)
Please tell us whether your studies or other studies or peer-reviewed articles have revealed any material disadvantages of your product.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Stock-Based Compensation, page 84
SEC asked (12)
Please tell us when you expect the study mentioned at the bottom of page 106 to be published.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Patents and Trademarks, page 115
SEC asked (13)
Please distinguish between patents that you own and patents that you license. Ensure that the quantification of the patents that you license does not include patents that have expired, and tell us the significance to your business of the patents you license that have recently expired or will expire in 2018.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

FDA Premarket Clearance and Approval Requirements, page 120
SEC asked (14)
Please clarify what you mean by "extended" and "standard" criteria. Underwriting, page 170
TMDX answered

No numbered answer found in the reply. Read the reply ↗

FDA Premarket Clearance and Approval Requirements, page 120
SEC asked (15)
Please specify the "certain other conditions" to the underwriters' obligations mentioned in the second paragraph.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Relationships, page 171
SEC asked (16)
Please provide more specific information regarding the past relationships with the underwriters mentioned in the last paragraph on page 171.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Note 2. Summary of Significant Accounting Policies · Property and Equipment, page F-12
SEC asked (17)
Please tell us how you determined that OCS Consoles have an estimated useful life of five years.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Inventory, page F-13
SEC asked (18)
You disclose that inventory is valued at the lower of cost or market value and that you establish provisions for excess and obsolete inventory. Please revise the policy to comply with the lower of cost or net realizable value requirements of ASC 330-10-35-1B. Additionally, revise to disclose how your accounting for excess or obsolete inventory complies with ASC 330-10-35-14 and SAB Topic 5.BB.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Revenue Recognition, page F-15
SEC asked (19)
You disclose that when you loan the OCS Console to customers you do not require minimum purchase commitments. Clarify if any of your sales agreements contain minimum purchase commitment. Please also tell us how you have determined the relative fair value allocated to the OCS Console deliverable in the multiple-element arrangement under ASC 605-25-15-3 and 15-3A.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

Note 15. Segment Reporting and Geographic Data , page F-46
SEC asked (20)
You discuss throughout the filing that you have organ-specific disposable sets and OCS Consoles. We also see on page 72 that these classes of disposable sets have different selling prices and gross margins. Please revise the filing to provide product line disclosures for each class of the organ-specific disposable sets as required by ASC 28010-50-40.
TMDX answered

No numbered answer found in the reply. Read the reply ↗

General
SEC asked (1)
Given your current level of development and your net revenue for the past three fiscal years, it does not appear appropriate to refer in your graphics to "Expanding the rate of successful transplant and improving clinical outcomes to save more lives." Please advise or revise.
TMDX answered
In response to the Staff’s comment, the Company has revised the graphic on the inside front cover of Amendment No. 1 to delete the phrase “Expanding the rate of successful transplants and improving clinical outcomes to save more lives.”
Read in the reply
Our restated articles of organization will designate the Business Litigation Session, page 53
SEC asked (2)
We note that your restated articles of organization will designate the Business Litigation Session of the Superior Court of Suffolk County, Massachusetts (or, if any only if the Business Litigation Session of the Superior Court of Suffolk County lacks jurisdiction, another state or federal court located within the Commonwealth of Massachusetts) as the sole and exclusive forum for any derivative action or proceeding
Rest of the question

brought on your behalf. Please disclose whether this provision will apply to actions arising under the Securities Act or Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision will apply to Securities Act claims, please also revise your registration statement to disclose this information and to state that there is uncertainty as to whether a court would enforce such provision, and to state that stockholders will not be deemed to have waived the company's compliance with the federal securities laws and the rules and regulations thereunder. If this provision will not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly.

TMDX answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 53 and 174 of Amendment No. 1 to clarify that the forum selection provision identifying the Business Litigation Session of the Superior Court of Suffolk County, Massachusetts (or, if and only if the Business Litigation Session of the Superior Court of Suffolk County, Massachusetts lacks jurisdiction, another state or federal court located within the Commonwealth of Massachusetts) as the exclusive forum for certain litigation, including any ”derivative action”, will not preclude or contract the scope of
Rest of the answer

exclusive federal or concurrent jurisdiction for actions brought under the Securities Exchange Act of 1934, as amended, or the Securities Act or 1933, as amended, or the respective rules and regulations promulgated thereunder. In addition, the Company is filing as Exhibit 3.3 to Amendment

No. 1 the form of the Company’s Restated Articles of Organization, which will be effective prior to the consummation of the offering to be made pursuant to the Registration Statement, to clarify the Company’s exclusive forum provision.

Read in the reply
Consolidated Balance Sheet, page F-3
SEC asked (3)
Tell us why, in the pro forma column, you present the $331 million amount of your no par value common stock in the Additional Paid-in Capital caption. We note that in the Capitalization table on page 60 you present the amount in the pro forma Common Stock caption. Please revise the filing to correctly and consistently present these amounts. Exhibits
TMDX answered
In response to the Staff’s comment, the Company has revised the disclosure on page F-3 of Amendment No. 1 to fix a typographical error that appeared in the unaudited pro forma balance sheet column in the prior filing of the Registration Statement. The revised disclosure in the unaudited pro forma balance sheet column on page

F-3 of Amendment No. 1 correctly presents the $331 million amount of the Company’s no par value common stock in the Common Stock caption.
Read in the reply
Consolidated Balance Sheet, page F-3
SEC asked (4)
Please file as an exhibit the waiver mentioned on page 31.
TMDX answered
In response to the Staff’s comment, the Company is filing the waiver mentioned on page 31 as Exhibit 10.35 to Amendment No. 1.
Read in the reply

Also in this review: company letter, Apr 16, 2019, company letter, Apr 29, 2019

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 10 letters filed since 2018-11-16. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.